Abstract

Objective: To synthesize the current scientific evidence regarding the long-term health consequences of gonadectomy in companion dogs and to evaluate the emerging role of hormone replacement therapy (HRT) and hormone-sparing sterilization as longevity interventions.

Background: Traditional spay/neuter surgery, while a cornerstone of population control, induces a state of hormonal deficiency characterized by the loss of sex hormones and a chronic, supraphysiologic elevation of Luteinizing Hormone (LH). A growing body of evidence links this endocrine disruption to an increased risk of orthopedic diseases, metabolic disorders, specific cancers, and accelerated frailty in senior dogs. This brief reviews the mechanisms of this hormonal fallout and assesses the data supporting therapeutic interventions.

Methods: A comprehensive review of recent veterinary and gerontological literature was conducted, focusing on studies from the Dog Aging Project, clinical trials on testosterone replacement (e.g., Brent et al., 2025), and epidemiological studies on the health outcomes of sterilized versus intact dogs (e.g., Kutzler 2020, Waters et al. 2025, Zink et al. 2023).

Results: The data confirm that while sterilization may increase overall lifespan, it is associated with a higher risk of death from cancer and an increased incidence of numerous chronic diseases. Chronically elevated LH is identified as a key driver of this pathology. Restoring physiological levels of testosterone or estrogen and/or suppressing LH with GnRH agonists (e.g., Deslorelin) shows significant promise in mitigating these risks. Furthermore, hormone-sparing sterilization techniques (vasectomy, hysterectomy) are shown to provide the health benefits of intact hormones without the risk of unwanted reproduction.

Conclusion: A paradigm shift is occurring in veterinary medicine, moving from a universal recommendation for early gonadectomy to a more individualized approach. For longevity-focused owners, understanding the hormonal consequences of sterilization and exploring options like hormone-sparing procedures and HRT offers a powerful, evidence-based strategy to improve healthspan and combat age-related disease in senior dogs.

Hormone Replacement Therapy for Senior Dogs

1. Key Findings

Hormone replacement therapy (HRT) for senior dogs is a paradigm-shifting approach to veterinary geriatrics, moving beyond simple disease management to address the foundational endocrine changes that drive aging. The central finding is that traditional spay/neuter surgery (gonadectomy), while effective for population control, creates a state of profound hormonal disruption with significant, lifelong health consequences. The loss of sex hormones (testosterone, estrogen) and the subsequent, dramatic elevation of Luteinizing Hormone (LH) are now linked to a wide range of diseases previously considered unavoidable aspects of aging. Emerging research demonstrates that restoring physiological hormone levels and suppressing chronic LH elevation can mitigate these risks, improve quality of life, and potentially extend healthspan.

2. Data and Statistics

The case for re-evaluating gonadectomy and considering HRT is built on a growing body of compelling data:

• The LH Surge: Following gonadectomy, the negative feedback loop of the hypothalamic-pituitary-gonadal (HPG) axis is broken. This results in a sustained, supraphysiologic surge of Luteinizing Hormone (LH), with levels reaching up to 30 times higher than those in intact dogs [9]. This chronic LH elevation is now considered a primary driver of many post-sterilization health issues.

• Orthopedic & Metabolic Disease: Gonadectomized dogs have a significantly higher incidence of hip dysplasia and cranial cruciate ligament rupture [1]. They are also twice as likely to develop diabetes mellitus and 30% more likely to develop hypothyroidism, independent of obesity [1].

• Cancer Risk: While sterilization eliminates the risk of gonadal cancers and reduces the risk of mammary tumors (if performed early), it has been associated with an increased risk of other, often more aggressive cancers, including lymphoma, mast cell tumors, and hemangiosarcoma [1].

• Frailty and Longevity: A 2025 study on long-lived Rottweilers found that each additional year of intact hormonal status reduced the risk of death associated with frailty by approximately 1%. Dogs neutered before age two had a 16% increase in mortality risk for every small increase in their frailty score, while those intact for over 10 years showed no increased mortality risk with frailty, suggesting their hormonal status provided a powerful buffer against age-related decline [2].

• The Lifespan Paradox: A large-scale 2013 study from the Dog Aging Project found that sterilized dogs lived longer on average (13.8% for males, 26.3% for females) [5]. However, this is likely confounded by factors such as improved access to veterinary care for owned, sterilized pets and a decreased risk of death from infectious disease or trauma. The study also confirmed an increased risk of death from cancer in the sterilized group.

3. Expert Opinions and Quotes

The shift towards a more nuanced view of canine hormones is being led by a group of pioneering researchers and veterinarians. Their work challenges decades of established practice and advocates for a more individualized, health-focused approach.

"Male dogs with the shortest duration of testis exposure had a very high mortality risk associated with late-life frailty, whereas the mortality consequence of increasing frailty was erased in males with the longest gonad exposure." — Dr. David Waters, PhD, DVM, Director, Center for Exceptional Longevity Studies [2]

This quote from the lead author of the Rottweiler frailty study encapsulates the core finding that endogenous hormones provide a powerful protective effect against age-related decline. The research of Dr. Michelle Kutzler at Oregon State University has been instrumental in elucidating the widespread negative effects of elevated LH, linking it to everything from obesity and urinary incontinence to cognitive dysfunction and cancer [1].

"Given the relatively low risk of these alternative surgeries, particularly in the hands of experienced veterinary practitioners, veterinarians might consider offering these alternative reproductive surgeries to allow dogs to obtain these benefits without experiencing unintentional reproduction." — Dr. Chris Zink et al., JAVMA 2023 [4]

This recommendation, from a study of over 6,000 dogs, highlights the growing consensus that hormone-sparing sterilization options, such as vasectomy and ovary-sparing spay (hysterectomy), are viable and medically preferable alternatives to traditional gonadectomy for many dogs.

4. Emerging Trends and Predictions

The field of canine HRT is poised for rapid advancement, driven by several key trends:

• Standardization of HRT Protocols: The recent publication of the first formal safety and dosing study on testosterone cypionate in neutered dogs is a landmark event [3]. This will pave the way for standardized, evidence-based protocols for testosterone replacement, moving it from a niche practice to a more mainstream therapeutic option. Similar research is expected for estrogen and other hormones.

• Rise of Hormone-Sparing Sterilization: As awareness grows, demand for vasectomy and ovary-sparing spay (hysterectomy) will increase. The UC Davis breed-specific guidelines, updated in 2024, which recommend delaying neutering for many large breeds, will further accelerate this trend [6].

• LH Suppression as a Therapeutic Target: The use of GnRH agonist implants like Deslorelin (Suprelorin®) to suppress the chronically elevated LH levels in sterilized dogs is a primary emerging strategy. This offers a way to mitigate the negative health consequences of gonadectomy even if sex hormone replacement is not pursued.

• The Rapamycin Revolution: The Dog Aging Project's TRIAD (Test of Rapamycin in Aging Dogs) clinical trial is one of the most anticipated studies in veterinary longevity science [8]. Rapamycin, an mTOR inhibitor, has shown remarkable life-extending effects in laboratory animals. A positive outcome in this large-scale canine trial could introduce an entirely new class of longevity therapeutics, which may be used in conjunction with HRT.

5. Controversial Viewpoints or Debates

The move towards HRT and hormone-sparing techniques is not without controversy. It directly challenges the long-held veterinary consensus that early spay/neuter is a universal good.

• Population Control vs. Individual Health: The primary argument for traditional spay/neuter remains population control. Proponents argue that the risk of unwanted litters outweighs the long-term health risks for an individual animal. This debate pits a public health goal against an individual wellness goal.

• The Lifespan Paradox: As noted, the finding that sterilized dogs live longer on average is a key point of contention [5]. HRT advocates argue this is a statistical artifact of better overall care and different causes of death, while opponents see it as evidence that sterilization is not broadly detrimental.

• Mammary Cancer and Pyometra Risk: The undeniable benefit of early spaying is a dramatically reduced risk of mammary cancer and the complete elimination of pyometra, a life-threatening uterine infection. This remains a powerful argument against hormone-sparing alternatives for female dogs, although the risk of pyometra is eliminated with an ovary-sparing spay (hysterectomy).

• Mainstream Veterinary Resistance: Many veterinarians and major organizations like the AVMA and ASPCA have been slow to adopt the new research, citing the need for more long-term data and prioritizing the established benefits of traditional sterilization. This creates a significant gap between cutting-edge research and standard clinical practice.

6. Practical Implications for Pet Owners

For longevity-focused pet owners, this new landscape requires a proactive, evidence-based approach in partnership with a forward-thinking veterinarian.

1. Rethink Sterilization: Do not automatically opt for traditional spay/neuter. Research the UC Davis breed-specific guidelines [6] and discuss hormone-sparing options like vasectomy or ovary-sparing spay with your veterinarian. If you have a large-breed dog, delaying sterilization until after physical maturity (1-2 years) is strongly recommended.

2. Test, Don't Guess: If you have a senior dog that is already sterilized and showing signs of aging (muscle loss, cognitive decline, low energy, skin issues), ask your veterinarian about a full hormone panel. This should include not just thyroid levels, but also testosterone, estrogen, and crucially, Luteinizing Hormone (LH).

3. Consider HRT: Based on test results, discuss specific replacement therapies. For neutered males with low testosterone and clinical signs, testosterone cypionate is now a well-supported option [3]. For spayed females with urinary incontinence or other signs of estrogen deficiency, Estriol (Incurin®) is a safe starting point.

4. Target the LH Surge: Regardless of sex hormone status, if your sterilized dog has markedly elevated LH, discuss the use of a Deslorelin (Suprelorin®) implant to suppress it. This may be one of the most impactful interventions for preventing long-term disease.

5. Don't Forget the Thyroid: Hypothyroidism is rampant in sterilized dogs and can mimic many other signs of aging. Ensure your dog's thyroid levels (including free T4) are checked annually and optimized with levothyroxine if necessary.

6. Find a Progressive Vet: The most critical step is to find a veterinarian who is knowledgeable about this emerging field. Use resources like the Parsemus Foundation's veterinarian directory to find practitioners who offer hormone-sparing sterilization and are open to discussing HRT [7].

References

[1] Kutzler, M. A. (2020). Possible Relationship between Long-Term Adverse Health Effects of Gonad-Removing Surgical Sterilization and Luteinizing Hormone in Dogs. Animals, 10(4), 599. https://pmc.ncbi.nlm.nih.gov/articles/PMC7222805/

[2] Waters, D. J., et al. (2025). Longer duration of intact hypothalamic–pituitary–gonadal (HPG) axis buffers the adverse impact of late-life frailty in male dogs. Scientific Reports. Sourced from summary at: https://newatlas.com/aging/hpg-axis-old-dogs-frailty-resilience/

[3] Brent, L., et al. (2025). Safety and dosing of testosterone for hormone restoration in neutered dogs. BMC Veterinary Research, 21(1), 449. https://pmc.ncbi.nlm.nih.gov/articles/PMC12239267/

[4] Zink, M. C., et al. (2023). Vasectomy and ovary-sparing spay in dogs: comparison of health and behavior outcomes with gonadectomized and sexually intact dogs. Journal of the American Veterinary Medical Association, 261(3), 366-376. https://avmajournals.avma.org/view/journals/javma/261/3/javma.22.08.0382.xml

[5] Hoffman, J. M., Creevy, K. E., & Promislow, D. E. (2013). Reproductive capability is associated with lifespan and cause of death in companion dogs. PloS one, 8(4), e61082. https://dogagingproject.org/scientific-results-reproductive-capability-is-associated-with-lifespan-and-cause-of-death-in-companion-dogs

[6] Hart, B. L., et al. (2020). Assisting Decision-Making on Age of Neutering for 35 Breeds of Dogs: Associated Joint Disorders, Cancers, and Urinary Incontinence. Frontiers in Veterinary Science, 7, 388. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2020.00388/full

[7] Parsemus Foundation. (n.d.). Hormone Restoration in Dogs. https://www.parsemus.org/project/hormone-restoration-in-dogs/

[8] Coleman, A. E., et al. (2025). Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial. GeroScience. https://pmc.ncbi.nlm.nih.gov/articles/PMC12181551/

[9] AKC Canine Health Foundation. (n.d.). Exploring How Spay/Neuter Impacts Long-Term Health in Dogs. https://www.akcchf.org/breakthrough/exploring-how-spayneuter/